Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies: a Randomized, Double Blind, Phase III Study Versus Allopurinol

NCT01724528 is registered in ClinicalTrials.gov with Menarini Group as lead sponsor.

NCT NCT01724528
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01724528 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies: a Randomized, Double Blind, Phase III Study Versus Allopurinol
Lead sponsor
Menarini Group
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2012
Completion date
October 31, 2013
Enrollment
346 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

tumor lysis syndrome